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Abstract No controlled trials have been performed to 
assess the efficacy of liver transplantation. Because of the 
marked improvement in survival after liver transplantation 
since 1981. random assignment of patients to a control 
group not undergoing transplantation is considered clini-
cally inappropriate. 
To assess the efficacy of liver transplantation in pa-
tients with primary biliary cirrhosis. we compared sur-
vival in 161 patients with this diagnosis who had under-
gone a liver transplantation with survival in patients 
with the same diagnosis who had been treated conser-
vatively. The comparison was performed with use of 
a recently developed statistical technique. the Mayo 
model. All patients had undergone liver transplanta-
tion between March 1980 and June 1987 and were 
TIVER transplantation has been accepted clinically 
L as a lifesaving treatment in various end-stage liv-
er diseases, including primary biliary cirrhosis.I,2 
However, no controlled trials have been performed to 
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followed for a median of 25 months. 
Three months after liver transplantation. the Kaplan-
Meier survival probabilities in the recipients were sub-
stantially higher than the Mayo-model "simulated-control" 
survival probabilities (P<0.001). At two years, the Kap-
lan-Meier survival probability was 0.74, whereas the 
mean Mayo-model survival probability was 0.31. The pa-
tients who were at low risk according to the Mayo model 
had the best probability of survival after liver transplanta-
tion; however. patients at all risk levels who had under-
gone liver transplantation had higher probabilities of sur-
vival than those who had no\. We conclude that liver 
transplantation is an efficacious treatment in patients with 
advanced primary biliary cirrhosis. (N Engl J Med 1989; 
320:1709-13.) 
evaluate the efficacy of this procedure. Indeed, be-
cause there has been a marked improvement since 
1981 ill survival after transplantation, random assign-
ment of patients with advanced liver disease to a non-
transplantation control group is considered to be clini-
cally inappropriate. 
AI the Mayo Clinic, a Cox regression model for 
predicting the probability of survival in patients with 
conservatively treated primary biliary cirrhusis has 
bl~en developed. 3 To provide control data for assessing 
'he efficacy of liver transplantation in improving 
survival, this model was applied to the combined pop-
ulation of patients with primary biliary cirrhosis 
who underwent transplantation at the University uf 
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Table 1. Values for Mayo-Model Variables in 161 Palients with 
Primary Biliary Cirrhosis Classified in Risk Subgroups. 
VARIABLB 
Age (yr) 
Bilirubin (mgldl)' 
Albumin (gldl) 
Prothrombin lime (sec) 
Edema seoret 
Risk seoret 
GIOU. I 
(N ~ 98) 
4SKR~UKR 
1OK1~UKO 
3.1 :to.S 
13.4:::1.4 
0.4:!:0.4 
7.4:t1.0 
GIOUP 2 
(N = 41) 
GROUP 3 ALL GROUPS 
(N = 22) (N - 161) 
m~an :SD 
47 KU~SKU 53.8±9.0 47.8±8.5 
24.1±12.2 OTKU~ 11.7 17.3=11.8 
2.7:t0.6 2.5:t0.4 2.9:::0.6 
15.1 :t2.5 19.5:!:5.7 14.6:::3.4 
0.8:t0.4 0.9:tO.2 0.5:::0.4 
9.2:tO.4 1O.4:tO.5 8.2::1.4 
-To conven to micromoles per liter. mUltiply by 17.1. 
t Acconllng to the Mayo model. 
vival curve for the 161 patients who had primary bili-
ary cirrhosis and the averaged Mayo-model curve for 
predicted survival. The two curves were similar dur-
ing the first three months after transplantation, a peri-
od during which the actual post-transplantation 
survival probability decreased sharply. The curve~ di-
verged later in the post-transplantation course. At one 
year after transplantation, the mean (±SD) actual 
survival probability was O.76±O.03, and the averaged 
Mayo-model survival probability was 0.45. At two 
years these values were 0.74±O.04 and 0.31, respec-
tively. The one-sample log-rank test showed the difTer-. 
ence between actual survival and Mayo-model surviv-
al to have a high level of significance (K = 372.5, 
P<O.OOI). 
In Figure 2, actual survival curves are compared 
with average survival curves based on the Mayo mod-
el for each of the three risk groups. At each risk level, 
the actual survival beyond three months after trans-
plantation was better than the survival predicted by 
the Mayo model (P<O.OOOI in all cases). 
Figure 2 shows clearly that patients who had lower 
risk scores according to the Mayo model (i.e., those 
who had better prognoses according to the model for 
survival with no treatment) also had better post-trans-
plantation survival. A Cox regression analysis assess-
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Figure 1. Actual (Kaplan-Meier) Survival aHer Transplantation in 
161 Patients with Primary Biliary Cirrhosis and Estimated Survival 
without Transplantation as Predicted by the Mayo Model (Simu-
lated Control). 
ing the association of the risk score with actual post-
transplantation survival indicated that each unit 
increase in the risk score increased the death rate by a 
factor of e027 == 1.30 (95 percent confidence interval, 
1.04 to 1.65). When the analysis was restricted to the 
first 90 days after transplantation, the factor increased 
to 1.63 (95 percent confidence interval, 1.23 to 2.1 j), 
showing the greater influence of risk on short-term 
survival. 
Twenty-eight of the 29 patients who underwent 
transplantation for reasons other than poor liver func-
tion were in Group 1, the group with the lowest risk. 
When the patients in Group 1 were subclassified ac-.. 
cording to the primary indication for liver transplan~ 
tation (poor liver function or associated 'complica-
tions), those who had poor liver function were found to 
be at higher risk in terms of the risk factors - notably 
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Figure 2. Actual (Kaplan-Meier) Survival after Transplantation in 
Three Risk Groups of Patients with Primary Biliary Cirrhosis and 
Estimated Survival without Transplantation as Predicted 
by the Mayo Model. 
The risk groups were formed on the basis of pretransplantation 
Mayo-model risk scores. Group 1 (low risk) comprised 98 patients 
with risk scores below 8.67; Grou'p 2 (medium risk). 41 palients 
with scores between 8.67 and 9.93; and Group 3 (high risk), 22 
patients with scores above 9.93. 
the bilirubin level (Table 2). The patients who under-
went transplantation because of poor liver function 
had a significantly higher survival rate than that pre-
dicted by the Mayo model (P<O.OOOI by one-sample 
log-rank test) (Fig. 3). However, survival after trans-
plantations performed for other reasons was similar to 
that predicted by the Mayo model (P = 0.376 by one-
sample log-rank test). 
There was evidence of an improvement in outcome 
over time. The group of 122 patients who under-
went transplantation after the introduction of OKT3 
therapy in November 198413 had better survival (one-
year Kaplan-Meier probability, 0.79±0.04) than the 
39 patients who underwent transplantation before 
that time (O.64±0.08). The difference in survival be-
tween these two periods remained statistically signifi-
cant after adjustment for the risk score. The adjusted 
death rate in the later period was estimated as 53 
II 
!. 
" 
'1 , 
I 
Pittsburgh and at the Baylor rniversit~ Hospital in 
Dallas. Actual survival after transplantatIOn was com-
pared with the survival estimated with use of the 
Mayo model. 
METHODS 
Mayo Model 
The control group used in our evaluation of the effect of liver 
transplantation on survival was formed according to data generated 
by the ;\hyo model for assessing survival in relation to the nawral 
history of primary biliary cirrhosis. 3 1.'his is ~ Cox r~gresslln 
model"; that uses a small number of mexpenslve, nonmvaSlve, 
and universally available measurements to predict survival in pa-
tients in whom this disease has not been treated. It was developed 
from a data base on 312 patients with primary biliary cirrhosis 
who had been referred to the Mayo Clinic between January 1974-
and May 1984 and who met standard el.igibility <ri.teria .for a .ran-
domized controlled clinical trial comparing D-pemcillamme with a 
placebo. Because this drug is now considered to be ineffectiv.e in 
primary biliary cirrhosis,6 having no apparent effect on. survIVal, 
biochemical changes, or histologic progression, all 312 pattents were 
considered to have received standard care (which has at most a 
negligible effect on the prognosis). Of these patients, 10 percent 
had undergone sclerotherapy or shunt procedures to comrol severe 
bleeding; these interventions are not thought to alter survival mean-
ingfully. Only 6 percent of the 312 patients received a liver 
transplant, and the follow-up of these patients was censored at 
transplantation. . 
The model was cross-validated in an independent patient popula-
tion - 106 patients who were eligible for the clinical trials but who 
chose not to participate. The model fit the data on survival well. As 
a result, the model was enhanced by combining the patients in the 
trial and outside it into a large group of 418 subjects for an estima-
tion of the values of model variables. The model was also found to 
assess risk in a way similar to that of other models that used Cox 
regression to evaluate survival in primary biliary cirr~osisKTKUKcinal­
Iy, extramural cross-validation in a group of 176 patients with the 
disease (141 from the New England Medical Center hospitals [Bos-
ton] and 35 from the Scott and White Clinic [Temple, Tex.]) estab-
lished the generalizability of the model (unpublished data). . 
The Mayo model uses the patient's age and four measures of hver 
function - total serum bilirubin and serum albumin concentra-
tions, prothrombin time, and a score for the clinical severity of 
edema. It combines these five variables to obtain a risk score (R) for 
each patient, in the following equation: R = 0.871 log, (bilirubin in 
milligrams per deciliter) - 2.53 log, (albumin in grams per decili-
ter) + 0.039 (age in years) + 2.38 log, (prothrombin time in sec-
onds) + 0.859 (edema score). 
The edema score is determined as follows: 0, minimal edema, 
defined as either edema requiring no diuretic therapy or as absence 
of edema; 0.5, moderate edema, defined as edema that resolved 
after treatment with diuretic agents, or edema for which no diuretic 
therapy was prescribed; and I, severe edema, defined as edema that 
persisted despite treatment with diuretic agents. 
The risk score is then used to produce a predicted-survival prob-
ability curve for that risk level. This curve indicates the probability 
that a patient will survive a given number of years after the risk 
score has been measured. Technical details are available e1se-
where. 3 
Patient Population 
Between March 1980 and June 1987, 981 patients underwent 
primary liver transplantation at the University of Pittsburgh or 
Baylor University, as described by Starzl et al.9 All the patients 
received base-line immunosuppressive treatment with cyclosparine 
and steroids. Beginning in November 1984, OKT3 monoclonal 
antibody was used to treat severe episodes of transplant rejection. 
Before transplantation, a diagnosis was established in each pa-
tient on the basis of clinical evaluation, biochemical values, Ills to-
logic assessment, and additional testing. Of the 981 patients, 161 
were given a diagnosis of primary biliary cirr.hasis (1-l9 women (93 
percent] and 12 men (7 percent]; all the patients except four were 
white [three black women and one black manz~K These ltil patients 
were treated between April 1980 and June 198,; the median monlh 
of transplantation was November 1985. The five "ariables for the 
~layo model were selected from the data .in the patienls'. medical 
records for the period immediately preceding transplantation. Fol-
low-up was completed in these patients as of December IB, 19BT~ 
The median duration of follow-up after transplantation was '2;) 
months. 
In 132 of the 161 patients with primary biliary cirrhosis, the 
primary indication for transplantation was. poor li"er f~nnionK 
However in the remaining 29 patIents, additional complICatIOns 
had led t~ transplantation: major esophageal varices with repeated, 
massive bleeding of the upper gastrointestinal tract, necessitating 
blood transfusions, despite repeated sclerotherapy (25 patients), 
and advanced osteodystrophy (4 patients). 
Statistical AnalysIs 
Survival time was defined as the time that elapsed from the initial 
liver transplantation until death or the date on which follow·up 
ended, whichever occurred first. All patients were included in the 
analysis, including those who received multiple transplal11s; the 101'-
ter were given no special treatment. Thirty-three pallerHs had un· 
dergone transplantation twice, and i others' t~ree time:. . 
Actual post-transplantation survi"al was eSl1mated with the Kap· 
lan-Meier product-limit estirnator. lo Predicted survival without 
transplantation was computed for each patient wilh use of Ihe 
~fayo model. The values for actual and model·pred,cted surVival 
were compared in two ways - graphically and by means of a 
statistical test. 
For the graphic method, the individual probabilities for predicted 
survival were averaged to produce a mean \!ayo-model sUf\wal 
curve, to be compared with the Kaplan-\leier curve. For purposes 
of presentation. the averaged Mavo-model survi\al probabtlHles 
were computed at only a few time points after transplantation ~­
three months, six months, and at yearly intervals - and then inter· 
polated linearlv. . . 
Statistical testing of differences between the survival predIcted 
with the Mavo model and the actual survival was performed with 
the one-sample log-rank test, II as implemented in the S.-\S I nsti-
tute's supplemental procedure SURVDIFF.12 This test uses the 
Mayo-model predicted-survival curve for each patient as a math-
ematical control for that patient. 
For further analysis, the 161 recipients of liver transplants were 
classified into three risk groups according to ~!ayo-rnodel risk score. 
The risk-score cutoff values dividing the groups (8.b7 and 9.93) 
were chosen sci that the three groups had roughly equal numbers of 
deaths that occurred in the first three months after transplantation. 
Group I, with the lowest risk, consisted of 98 patients, with .10 
deaths in the first three months. Group 2 had -H patterHs. wIfh 
10 deaths in the first three months. Group 3 had 22 patients, wilh 
nine deaths in the first three months. 
The relation between the Mayo-model risk score and the actual 
post-transplantation survival was assessed by tD~o Cox regression 
analyses. One analysis examined the entire lollo",'up penod, 
and the other was restricted to the first 90 days alter trall.'-
plantation. 
Temporal trends in post-transplantation outcome were assessed 
by subclassifying the patients into the 40 who underwent transplan· 
tation before OKT3 was used to treat severe rejection (\'overnber 
1984) and the 121 who underwent transplantation after that ,btc. 
Cox regression was used to compare survival in these two groups; 
differences in risk at base line were controlled for by including tlIe 
risk score from the Mayo model as a covariate. 
RESULTS 
Table I shows the descriptive statistics for the elltire 
study population and for each of the three risk grou ps. 
There were 41 deaths overall. 
Figure I shows the actual post-transplantation slIr-
